U.S. Oncology Devices Market to Hit USD 112.17B by 2035

Market Outlook

By 2035, the U.S. Oncology Devices Market is expected to reach approximately USD 112.17 billion, expanding at a CAGR of 9.60% during the forecast period 2026-2035. The market was valued at USD 44.85 billion in 2025, with historical analysis covering 2021-2024. Values in this report are expressed in USD billions. The estimate covers oncology-directed radiation therapy systems, cancer surgery and robotic platforms allocated to oncologic procedures, interventional oncology and tumor ablation devices, biopsy and lesion-localization products, brachytherapy systems, tumor treating field devices, and oncology-specific imaging, navigation, planning, and workflow technologies. It excludes anticancer drugs, laboratory-only in vitro diagnostics, and general-purpose imaging revenue not directly attributable to cancer workflows.

The U.S. oncology devices industry is entering a new capital and procedural expansion cycle as cancer incidence rises, survival improves, and treatment shifts toward earlier diagnosis, minimally invasive intervention, precision radiation, and technology-supported longitudinal care. An estimated 2,041,910 new cancer cases and 618,120 cancer deaths were expected in the United States in 2025. Approximately 88% of people diagnosed with cancer are age 50 or older, and 59% are age 65 or older, making oncology demand closely linked to Medicare coverage, aging demographics, and hospital capacity. The device market is therefore supported by both new-patient flow and a growing survivor population that requires surveillance, repeat imaging, local control procedures, recurrence management, and supportive interventions.

The market is moving beyond conventional linear accelerators, biopsy needles, surgical instruments, and basic image guidance toward integrated treatment ecosystems. Growth is concentrating in adaptive radiotherapy, MR-guided and CT-guided treatment, stereotactic radiosurgery, robotic cancer surgery, electromagnetic and optical navigation, cryoablation, microwave and radiofrequency ablation, irreversible electroporation, tumor treating fields, AI-assisted contouring, digital pathology-linked intervention planning, and distributed treatment models that extend selected care into outpatient and home settings. U.S. health systems increasingly evaluate these technologies through total episode economics, including treatment throughput, fraction reduction, operating room utilization, staff productivity, margin per case, referral capture, retreatment risk, and downstream complication cost.

The historical market expanded from USD 31.95 billion in 2021 to USD 41.15 billion in 2024. Growth during this period reflected recovery in cancer screening, biopsy, radiation therapy, and elective oncologic surgery; replacement of aging radiation oncology infrastructure; rising use of robotic and laparoscopic procedures; and broader adoption of image-guided ablation. In 2025, the market reached USD 44.85 billion as major health systems renewed capital equipment, community oncology networks added treatment capacity, and manufacturers commercialized software-enabled upgrades that increased the value of installed platforms without requiring a completely new treatment room.

Introduction

According to the U.S. Oncology Devices Market Report, the industry is shaped by a high and persistent cancer burden, a dense network of advanced hospitals, strong specialist referral systems, mature reimbursement pathways, and a regulatory environment that supports rapid clinical translation when safety and effectiveness are demonstrated. Oncology is one of the most device-intensive areas of U.S. healthcare because diagnosis and treatment depend on coordinated use of imaging, biopsy, surgical access, radiation delivery, ablation, localization, treatment planning, patient positioning, pathology integration, and long-term monitoring. The country also has 74 NCI-Designated Cancer Centers across 37 states and the District of Columbia, creating a concentrated group of institutions that influence evidence generation, specialist training, early adoption, and national treatment standards.

The market is not a uniform capital-equipment category. It combines high-value systems with recurring consumables, software subscriptions, service contracts, procedure-specific disposables, implanted or wearable therapeutic devices, and replacement components. Radiation oncology systems and robotic surgery platforms create large capital transactions and long service relationships. Biopsy needles, markers, ablation probes, access devices, surgical energy products, and brachytherapy accessories generate repeat procedural revenue. Software, AI, image registration, and workflow orchestration create additional value by improving utilization of existing assets. This mixed revenue structure makes the market attractive to diversified medtech companies and specialized innovators alike.

The economic context is equally important. U.S. hospital spending reached approximately USD 1.63 trillion in 2024, while national cancer care expenditures were estimated at USD 208.9 billion in 2020 and are expected to rise as the population ages and more patients live with cancer. Oncology service lines are strategically protected because they generate complex multidisciplinary activity across surgery, imaging, pathology, infusion, radiation therapy, and follow-up care. Capital committees therefore assess oncology devices not only on clinical superiority but also on whether the technology expands the treatable patient pool, reduces treatment time, supports outpatient migration, increases room utilization, and strengthens regional referral positioning.

From 2026 through 2035, the defining strategic shift will be from isolated devices to connected cancer-care platforms. Buyers will prefer technologies that link detection, staging, treatment planning, intervention, verification, and outcomes documentation. Manufacturers that can integrate imaging, procedure guidance, software, consumables, and data services will be positioned to compete for enterprise contracts rather than single-device purchases. At the same time, focused companies can gain share by solving high-cost workflow problems such as difficult lesion access, motion management, adaptive replanning, same-day biopsy-to-treatment coordination, or non-invasive therapy for patients who are poor surgical candidates.

Key Market Drivers: What’s Fueling the U.S. Oncology Devices Market Boom?

The first major driver is the scale and persistence of the U.S. cancer burden. More than two million new diagnoses in 2025 create recurring demand across the full device pathway, beginning with image-guided biopsy and localization and extending through surgery, radiation, ablation, and recurrence management. Breast cancer alone accounted for an estimated 316,950 invasive cases in 2025, while prostate cancer accounted for 313,780 cases, lung and bronchus cancer for 226,650 cases, and colorectal cancer for 154,270 cases. These high-volume tumor groups support large installed bases of radiation systems, surgical platforms, endoscopy devices, biopsy technologies, and interventional oncology tools. Less common cancers also create attractive premium niches when the required device is highly specialized.

A second driver is the aging population and the expansion of cancer survivorship. Cancer incidence rises sharply with age, and the U.S. had an estimated 18.6 million cancer survivors in 2025. The survivor population is projected to reach 22.4 million by 2035. This changes device demand from a one-time treatment event into a longitudinal care requirement. Survivors may need repeat imaging, surveillance biopsy, resection of recurrent or metastatic disease, radiation retreatment, venous access, local ablation, and management of treatment-related complications. Devices that can deliver precise repeat treatment while limiting injury to previously treated tissue are likely to gain value.

A third driver is the migration toward minimally invasive and organ-preserving treatment. Hospitals are expanding robotic surgery, laparoscopic and endoscopic resection, stereotactic radiation, percutaneous ablation, and image-guided local therapy because these approaches can reduce blood loss, length of stay, postoperative complications, and recovery time. In selected patients, cryoablation, microwave ablation, radiofrequency ablation, irreversible electroporation, focused ultrasound, or tumor treating fields can provide alternatives or complements to open surgery and systemic therapy. Adoption is strongest when the device expands eligibility for older, frail, or medically complex patients and when the procedure can be performed in a shorter-stay setting.

A fourth driver is the replacement and modernization cycle for radiation oncology infrastructure. Linear accelerators, treatment planning systems, patient positioning platforms, imaging components, and quality-assurance tools require periodic replacement, software upgrades, and cybersecurity support. The market is shifting toward adaptive workflows, high-definition onboard imaging, surface-guided radiation therapy, stereotactic capability, automated contouring, and shorter treatment courses. For health systems, the business case depends on the ability to treat more patients per day, reduce manual planning time, standardize protocols across sites, and avoid capital fragmentation across multiple vendor platforms.

A fifth driver is the growth of precision diagnosis and image-guided therapy. Oncology procedures increasingly depend on high-quality tissue acquisition, lesion localization, molecularly informed patient selection, and real-time visualization. Vacuum-assisted breast biopsy, navigational bronchoscopy, fusion-guided prostate biopsy, endoscopic ultrasound, cone-beam CT, intraoperative imaging, fluorescence guidance, and electromagnetic navigation are becoming embedded in treatment pathways. Devices that improve diagnostic yield or enable treatment in the same episode can reduce repeat procedures and accelerate time to therapy, which is valuable to patients, clinicians, and payers.

A sixth driver is hospital capital procurement behavior. Oncology programs are regional referral assets, and major investments can influence physician recruitment, payer contracting, and patient retention. Value analysis committees increasingly require a total-cost case that includes room construction, shielding, service agreements, disposable utilization, staffing requirements, downtime risk, training, interoperability, and reimbursement. Vendors that offer modular upgrades, enterprise analytics, predictable service, and multi-site standardization are advantaged. Conversely, technologies with high acquisition cost but weak throughput, limited indications, or uncertain reimbursement face longer sales cycles even when the clinical concept is compelling.

A seventh driver is the density of U.S. regulatory and clinical innovation. FDA oncology device activity spans radiation oncology, diagnostic imaging, tumor ablation, biopsy, soft-tissue markers, surgical guidance, and therapeutic devices. The market benefits from a large clinical trial network and sophisticated academic centers capable of evaluating new modalities. Recent approvals for home-compatible tumor treating fields and local breast tumor cryoablation demonstrate that device innovation is moving into disease areas traditionally dominated by surgery or drug therapy. Manufacturers that generate strong clinical evidence and integrate reimbursement planning early in development can accelerate adoption after authorization.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. oncology devices market is increasingly defined by precision, automation, adaptability, and workflow integration. The competitive objective is no longer simply to deliver radiation, remove tissue, or place an ablation probe. The leading platforms help clinicians identify the target, select the patient, plan the intervention, compensate for motion or anatomy change, verify treatment, and document outcomes. This creates a shift from product-level competition to platform-level competition, with imaging, software, disposables, service, and data becoming as important as the core hardware.

Adaptive radiation therapy is one of the most important innovation areas. Conventional radiation plans are created from a pre-treatment image, but patient anatomy can change during a multi-week course. Newer systems use high-quality onboard imaging, automated segmentation, deformable registration, and rapid replanning to adapt treatment closer to the time of delivery. MR-guided and advanced CT-guided workflows improve soft-tissue visualization and can support tighter margins around the tumor. The economic challenge is to make adaptation fast enough for routine use. Vendors are therefore competing on automation, image quality, treatment speed, and the ability to scale adaptive workflows beyond a small group of expert centers.

Stereotactic and hypofractionated treatment is another major innovation theme. Delivering fewer, more precise fractions can improve patient convenience and increase capacity, but it requires accurate imaging, motion management, immobilization, dosimetry, and quality assurance. This supports demand for high-performance linear accelerators, radiosurgery systems, surface tracking, respiratory gating, robotic couches, and software that automates plan generation and verification. As more tumor sites become eligible for shorter courses, hospitals can treat more patients without proportionally increasing room count, strengthening the capital return on advanced systems.

Robotic and image-guided surgery is expanding the addressable market for minimally invasive oncologic procedures. Robotic platforms are increasingly used in prostate, kidney, gynecologic, colorectal, thoracic, and selected head and neck procedures. Competition extends beyond robotic consoles to stapling, energy, visualization, fluorescence imaging, insufflation, access, and instrument ecosystems. Hospitals evaluate robotic oncology through operating room block utilization, surgeon recruitment, procedure conversion from open surgery, length of stay, and disposable economics. The strongest vendors create a repeatable workflow across multiple cancer specialties rather than relying on one high-volume procedure.

Interventional oncology innovation is broadening local tumor control. Microwave and radiofrequency systems are improving energy delivery and lesion predictability. Cryoablation offers visible ice-ball monitoring and is moving into selected breast, kidney, lung, bone, and soft-tissue applications. Irreversible electroporation is relevant where thermal injury to nearby vessels or ducts is a concern. Focused ultrasound and laser ablation extend non-incisional treatment into selected prostate, brain, bone, and soft-tissue indications. The commercial opportunity is strongest when manufacturers combine treatment probes with planning, navigation, temperature or energy monitoring, and standardized procedure protocols.

Biopsy and localization technologies are also becoming more sophisticated. The goal is to obtain adequate tissue with fewer passes, lower complication risk, and precise targeting. Growth areas include vacuum-assisted breast biopsy, robotic bronchoscopy, cone-beam CT-guided lung biopsy, fusion-guided transperineal prostate biopsy, endoscopic ultrasound-guided sampling, and markers that help surgeons or radiation oncologists relocate a lesion. As molecular testing requires sufficient high-quality tissue, device performance at the diagnostic stage can influence the entire treatment pathway. Technologies that reduce non-diagnostic samples and repeat biopsies can justify premium pricing.

AI and oncology informatics are emerging as a strategic layer across the market. AI is being used for image segmentation, organ-at-risk contouring, treatment planning, image registration, surgical guidance, patient positioning, workflow triage, and quality checks. The near-term value is operational rather than autonomous clinical decision-making. U.S. providers are most likely to pay for software that reduces planning time, standardizes performance across sites, flags exceptions, and helps scarce specialists manage larger volumes. Cybersecurity, interoperability, and transparent validation will remain central procurement requirements.

Manufacturers are also raising the bar through evidence and implementation support. Device authorization alone does not guarantee adoption. Hospitals expect clinical training, credentialing pathways, service coverage, workflow redesign, health economic models, and real-world performance data. Companies that can shorten the learning curve and demonstrate improvements in throughput, complications, repeat procedures, or treatment completion will be better positioned to defend premium pricing. In oncology, implementation quality directly affects clinical outcomes, making field support and provider education meaningful competitive assets rather than secondary services.

Segmentation Insights

The U.S. Oncology Devices Market is segmented on the basis of product category, cancer application, end user, and technology type.

By Product Category

Radiation therapy systems represent the largest high-value product category. The segment includes linear accelerators, stereotactic radiosurgery platforms, proton therapy systems, brachytherapy afterloaders, treatment planning systems, oncology information systems, patient positioning equipment, motion-management devices, dosimetry, and quality-assurance technologies. Demand is supported by replacement of installed equipment, expansion of regional treatment capacity, and adoption of adaptive and image-guided workflows. Linear accelerators remain the commercial center of the segment, while software, onboard imaging, and service contracts are increasing revenue per installed system.
Surgical oncology devices form a broad procedural category that includes robotic systems, laparoscopic and endoscopic instruments, surgical energy devices, stapling, resection tools, intraoperative imaging, fluorescence guidance, access platforms, and specialized instruments for breast, thoracic, urologic, gynecologic, colorectal, neurologic, and head and neck cancers. Growth is driven by minimally invasive conversion and the need to preserve organ function. Hospitals favor platforms that can support multiple specialties and create high recurring instrument utilization. Competitive differentiation increasingly depends on visualization, ergonomic control, tissue handling, and integration with preoperative and intraoperative imaging.
Interventional oncology and tumor ablation devices are among the fastest-growing categories. The segment includes microwave ablation, radiofrequency ablation, cryoablation, irreversible electroporation, laser ablation, focused ultrasound, embolization delivery devices, and image-guided access systems. These technologies are used for primary tumors, metastatic lesions, palliation, and local control in patients who may not be ideal surgical candidates. Growth is strongest in liver, lung, kidney, bone, prostate, and selected breast or pancreatic applications. Procedure expansion depends on evidence, specialist training, and access to high-quality imaging guidance.
Biopsy, localization, and tissue acquisition devices provide a stable recurring-consumable base. Products include core needles, vacuum-assisted breast biopsy systems, endoscopic ultrasound needles, bronchoscopic biopsy tools, prostate biopsy devices, fiducial markers, localization wires and seeds, radiopaque markers, and specimen-handling systems. The segment benefits from screening volume and the increasing tissue requirements of precision oncology. Providers value devices that improve diagnostic yield, reduce bleeding or pneumothorax risk, and support accurate lesion relocation for surgery or radiation.
Oncology-specific imaging, navigation, and treatment support devices include cone-beam CT, intraoperative ultrasound, surgical navigation, electromagnetic tracking, surface-guided radiation systems, patient immobilization, image fusion, and dedicated oncology workflow software. These products may be lower in unit value than a treatment system but can materially influence utilization and outcomes. Growth is supported by the need to treat smaller lesions, compensate for motion, reduce setup error, and coordinate care across imaging, surgery, pathology, and radiation oncology.

By Cancer Application

Breast cancer is one of the largest device application segments because of the size of the diagnosed population and the number of device touchpoints across screening follow-up, biopsy, localization, breast-conserving surgery, mastectomy, reconstruction, radiation therapy, and recurrence management. In 2025, the United States was expected to record approximately 316,950 invasive female breast cancer cases. Growth opportunities include vacuum-assisted biopsy, wireless localization, intraoperative margin assessment, image-guided partial breast treatment, hypofractionated radiation, cryoablation for selected low-risk disease, and advanced reconstruction technologies.
Lung cancer is a high-priority application due to its mortality burden and the difficulty of accessing small peripheral lesions. The segment includes navigational bronchoscopy, robotic bronchoscopy, endobronchial ultrasound, percutaneous biopsy, thoracic surgery instruments, stereotactic body radiation therapy, ablation, and tumor treating field technologies. Approximately 226,650 lung and bronchus cancer cases were expected in 2025. Expansion of lung screening creates a larger pipeline of earlier-stage nodules, increasing demand for technologies that can diagnose and treat small lesions accurately while minimizing pneumothorax, unnecessary surgery, and delays between diagnosis and treatment.
Prostate cancer is a major application segment with approximately 313,780 expected cases in 2025. Device demand spans MRI-ultrasound fusion biopsy, transperineal access, robotic prostatectomy, external beam radiation, brachytherapy, focal ablation, high-intensity focused ultrasound, laser ablation, and image-guided treatment planning. Growth is supported by the large patient pool and the increasing use of risk-stratified treatment. The device opportunity is concentrated in technologies that reduce urinary, sexual, or rectal complications and enable precise focal or hypofractionated therapy.
Colorectal and gastrointestinal cancers support demand for endoscopy, biopsy, surgical stapling, robotic and laparoscopic resection, intraoperative imaging, radiation therapy, and liver-directed intervention. Approximately 154,270 colorectal cancer cases were expected in 2025. Device utilization is shaped by screening detection, minimally invasive colectomy, rectal cancer organ-preservation strategies, and treatment of liver metastases. Technologies that improve endoscopic detection, margin control, anastomotic integrity, pelvic visualization, and precise treatment of metastatic lesions have strong clinical and economic relevance.
Liver, kidney, pancreatic, brain, bone, gynecologic, and other solid tumors create a diverse set of high-value niches. Kidney cancer supports partial nephrectomy, robotic surgery, cryoablation, and microwave ablation. Liver cancer and metastases drive ablation, embolization, navigation, and stereotactic radiation. Pancreatic cancer is creating interest in irreversible electroporation and tumor treating fields. Brain tumors support radiosurgery, navigation, laser interstitial thermal therapy, and intraoperative imaging. These applications may have smaller case volumes than breast or prostate cancer, but their device intensity and clinical complexity can produce attractive revenue per procedure.

By End User

Hospitals and integrated health systems are the dominant end users. They account for most radiation therapy capital purchases, robotic oncology procedures, complex cancer surgery, advanced imaging, and inpatient interventional oncology. Large systems increasingly standardize vendors across multiple hospitals and satellite centers, negotiate enterprise service agreements, and use centralized value analysis. Their purchasing decisions are influenced by total cost of ownership, network-wide interoperability, service response, cybersecurity, clinician preference, and the ability to shift appropriate treatments to outpatient departments.
Comprehensive cancer centers and large community oncology networks are strategically important because they combine high patient volume with multidisciplinary treatment. These organizations invest in advanced radiation systems, brachytherapy, biopsy, image guidance, navigation, and procedure support to retain patients within the network. Community networks are particularly relevant for distributed radiation therapy and diagnostic access. Vendors that offer scalable platforms, remote planning support, centralized analytics, and consistent protocols across hub-and-spoke sites can gain share in this end-user group.
Academic medical centers and NCI-Designated Cancer Centers are critical early adopters and evidence generators. They lead clinical trials, evaluate new modalities, train specialists, and influence national guidelines. High-complexity technologies such as MR-guided radiotherapy, proton therapy, adaptive planning, laser ablation, robotic bronchoscopy, and novel tumor treating fields often penetrate these institutions first. Procurement is evidence-intensive, and adoption may depend on research collaboration, data access, and integration with clinical trial workflows.
Ambulatory surgery centers, outpatient imaging centers, and office-based specialty practices are growing end users for selected oncology procedures. Breast biopsy, prostate biopsy, endoscopy, venous access, minor tumor excision, and certain image-guided interventions can be performed outside the inpatient hospital. These settings prioritize compact equipment, low infrastructure requirements, rapid turnover, predictable disposable cost, and straightforward reimbursement. Device designs that require less shielding, smaller footprints, simplified sterilization, or fewer specialized staff are better aligned with outpatient economics.
Home-based and distributed oncology care represents a smaller but high-growth end-user segment. Portable tumor treating field systems are the clearest example of a therapeutic oncology device used outside the hospital. Remote monitoring, connected symptom tracking, and home-compatible supportive devices are also expanding. The commercial model differs from traditional capital equipment because it depends on patient adherence, recurring supplies, field support, and payer authorization. Technologies that safely move selected treatment or monitoring into the home can reduce travel burden and extend access beyond major cancer centers.

By Technology Type

External beam and particle therapy technologies dominate market value. This segment includes conventional and advanced linear accelerators, stereotactic systems, proton therapy, image guidance, motion management, and adaptive planning. The growth rate is driven less by basic beam generation and more by imaging quality, automation, workflow speed, and software. Proton therapy remains a high-capital niche with selective expansion, while photon-based systems continue to benefit from broader indications and lower infrastructure burden.
Image-guided and robotic technologies are among the fastest-growing technology types. They include robotic surgery, robotic bronchoscopy, surgical navigation, cone-beam CT guidance, fusion imaging, fluorescence visualization, and surface tracking. These systems improve access to difficult anatomy and can make procedures more reproducible. Revenue growth is supported by capital purchases and recurring instruments, but adoption depends on procedure volume and clinician training. Platforms with multi-specialty use are more likely to achieve favorable utilization.
Energy-based ablation technologies include microwave, radiofrequency, cryogenic, electroporation, laser, and focused ultrasound systems. These technologies compete on ablation-zone predictability, treatment time, collateral tissue protection, imaging visibility, and usability in challenging anatomy. The category is expanding as local treatment becomes more integrated with systemic therapy and as multidisciplinary tumor boards consider ablation for oligometastatic disease, palliation, and patients with limited surgical options.
Implantable, wearable, and field-based therapeutic technologies are emerging as a differentiated segment. Tumor treating fields deliver alternating electrical fields through patient-worn arrays and create a recurring home-treatment model. Brachytherapy seeds, applicators, and localized radiation sources also fit within this segment. These technologies can offer high treatment specificity, but commercial success depends on adherence, patient selection, reimbursement, and strong clinical support. The segment is likely to expand as device therapy enters cancer types historically managed almost entirely with drugs and surgery.
Software-enabled and AI-assisted technologies are becoming a cross-market growth layer. Applications include automated contouring, treatment planning, image registration, dose calculation, workflow scheduling, quality assurance, surgical guidance, and clinical decision support. Software may represent a smaller standalone revenue pool than capital systems, but it increasingly determines the performance and differentiation of hardware. Vendors that provide validated, interoperable, and continuously updated software can increase installed-base retention and create recurring revenue beyond the original equipment sale.

Regional Insights: Where the Market is Growing Fastest

The U.S. Oncology Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance differs according to cancer incidence, population age, specialist density, academic and NCI-designated center concentration, hospital capital budgets, outpatient network development, and access to advanced radiation and surgical technologies. The South is the largest regional market because it combines the highest absolute cancer burden with fast-growing metropolitan health systems. The West is expected to record the fastest growth through 2035 due to technology adoption, population expansion, and strong interventional and digital oncology ecosystems. The Northeast has the highest concentration of complex academic care, while the Midwest provides a large, stable procedure base and an important medtech manufacturing and clinical research footprint.

South

The South is the dominant regional market, accounting for an estimated USD 16.15 billion in 2025 and approximately 36% of national oncology device revenue. The region includes Alabama, Arkansas, Delaware, the District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. These states represented approximately 802,260 expected new cancer cases in 2025, nearly 39% of the national total. The region combines high disease burden, large and aging populations, rapid metro growth, and a mix of nationally recognized cancer centers and underserved rural markets.

Florida and Texas are the two largest state opportunities. Florida was expected to record approximately 171,960 new cancer cases in 2025, while Texas was expected to record 150,870. Florida has a large Medicare-aged population and high demand for radiation therapy, prostate and breast cancer procedures, skin cancer treatment, image-guided biopsy, and outpatient oncology services. Texas benefits from major medical hubs in Houston, Dallas-Fort Worth, Austin, and San Antonio, as well as large integrated systems and internationally recognized cancer programs. Both states can support premium technologies, but vendors must manage price variation between major academic centers, community networks, and rural affiliates.

North Carolina, Georgia, Virginia, Maryland, and Tennessee are high-value growth states. North Carolina was expected to record 71,320 new cases in 2025, Georgia 66,210, Virginia 50,510, Maryland 37,200, and Tennessee 42,750. These markets are adding cancer centers, ambulatory sites, and regional radiation capacity. North Carolina and Maryland benefit from strong research and life-science ecosystems, while Georgia, Tennessee, and Virginia combine large referral networks with expanding suburban populations. Demand is strong for robotic surgery, breast biopsy, lung navigation, stereotactic radiation, and distributed treatment planning.

Alabama, Arkansas, Kentucky, Louisiana, Mississippi, Oklahoma, South Carolina, and West Virginia have substantial cancer burden but uneven access to advanced oncology technology. Lung cancer, colorectal cancer, and other tobacco- or obesity-associated cancers contribute to procedural demand. Major urban referral centers can support advanced platforms, while smaller communities require cost-efficient systems, mobile or satellite services, and reliable remote support. Manufacturers that can combine high-end flagship installations with scalable community solutions are well positioned. The South is projected to reach approximately USD 39.50 billion by 2035, representing a regional CAGR of about 9.36%.

West

The West represented an estimated USD 10.77 billion in 2025 and is expected to be the fastest-growing region. It includes Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming. These states accounted for approximately 423,900 expected new cancer cases in 2025. The region combines the scale of California, fast-growing populations in Arizona, Nevada, Utah, and Colorado, and a strong concentration of medtech, digital health, imaging, and venture-backed oncology innovation.

California is the most important state market in the West, with approximately 199,970 expected new cancer cases in 2025. The state has a large academic and integrated health-system base and is an early adopter of advanced radiotherapy, robotic surgery, interventional oncology, AI-enabled imaging, and digital workflow platforms. High labor and construction costs create demand for technologies that increase throughput, reduce treatment fractions, or avoid major facility expansion. California is also important for clinical trials, commercialization partnerships, and adoption by large payer-provider organizations.

Arizona, Washington, Colorado, Oregon, Nevada, and Utah are attractive growth markets. Arizona was expected to record 42,560 new cases in 2025, Washington 46,500, Colorado 29,020, Oregon 26,980, Nevada 17,540, and Utah 14,120. Arizona and Nevada benefit from rapid population growth and aging. Washington and Oregon have sophisticated integrated delivery systems and strong interest in connected care. Colorado and Utah support advanced specialty programs and technology-oriented provider networks. These states are likely to expand stereotactic radiation, robotic surgery, ablation, and outpatient diagnostic capacity.

Idaho, Montana, New Mexico, Wyoming, Alaska, and Hawaii are smaller markets with access and geography challenges. They create opportunities for compact platforms, satellite cancer centers, teleplanning, mobile services, and technologies that reduce repeated travel. Service reliability and remote support are particularly important because equipment downtime can force patients to travel long distances. The West is projected to reach approximately USD 29.20 billion by 2035, implying a regional CAGR of about 10.49%. Its share is expected to rise as precision oncology becomes more software-driven, ambulatory, and connected.

Northeast

The Northeast accounted for an estimated USD 9.87 billion in 2025. The region includes Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. These states represented approximately 374,950 expected new cancer cases in 2025. Although the region has a smaller population than the South, it produces high oncology device revenue per patient because of its concentration of academic hospitals, complex referrals, advanced radiation programs, and early adoption of premium technologies.

New York, Pennsylvania, New Jersey, and Massachusetts anchor the region. New York was expected to record approximately 123,430 new cancer cases in 2025, Pennsylvania 90,240, New Jersey 59,840, and Massachusetts 44,000. These states contain dense networks of academic medical centers, comprehensive cancer programs, community affiliates, and specialty hospitals. They are major markets for adaptive radiation, proton therapy, radiosurgery, robotic surgery, navigation, breast diagnostics, and clinical-trial technologies. Procurement is rigorous and evidence-driven, but successful adoption can influence national practice patterns.

Connecticut, Maine, New Hampshire, Rhode Island, and Vermont are smaller state markets that benefit from regional referral relationships. Connecticut supports high-acuity care and strong ties to academic systems in New York and Massachusetts. Northern New England has older populations and more dispersed geography, creating demand for community radiation capacity, efficient treatment schedules, remote planning, and reliable service. Vendors must balance advanced technology at regional hubs with cost-effective platforms in community settings.

The Northeast is expected to reach approximately USD 24.50 billion by 2035, representing a CAGR of about 9.52%. Growth will be supported by replacement of mature installed bases, adaptive radiotherapy, software upgrades, precision surgery, and advanced biopsy or navigation. Population growth is slower than in the South and West, but the region will remain one of the most profitable markets because of procedure complexity, specialist density, and the willingness of leading institutions to adopt technologies backed by strong evidence.

Midwest

The Midwest represented an estimated USD 8.06 billion in 2025 and accounted for approximately 440,800 expected new cancer cases. The region includes Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. It combines major academic and urban cancer centers with large community hospital networks and extensive rural referral areas. Demand is stable across radiation therapy, cancer surgery, biopsy, endoscopy, and interventional oncology.

Illinois, Ohio, Michigan, Minnesota, Missouri, and Wisconsin are the leading state markets. Illinois was expected to record 78,870 new cases in 2025, Ohio 77,010, Michigan 66,040, Minnesota 37,650, Missouri 39,220, and Wisconsin 39,940. Chicago, Cleveland, Columbus, Detroit, Minneapolis-St. Paul, St. Louis, and Milwaukee support high-volume academic and integrated oncology programs. Minnesota also has a strong medical device ecosystem, which supports clinical collaboration and early evaluation of new technologies.

Indiana, Iowa, Kansas, Nebraska, North Dakota, and South Dakota provide steady demand but have more dispersed populations. These states are important for hub-and-spoke radiation networks, remote planning, mobile imaging, and technologies that reduce travel or treatment duration. Community hospitals prioritize service reliability, predictable ownership cost, and multi-purpose systems. Vendors that can support regional training and maintain uptime across geographically dispersed sites can build durable share.

The Midwest is projected to reach approximately USD 18.97 billion by 2035, representing a CAGR of about 8.94%. Growth will be slower than in the West but remains attractive because of the large cancer burden, mature treatment infrastructure, and replacement demand. The region is especially favorable for vendors with strong clinical education, enterprise contracting, service coverage, and cost-effective upgrade paths for existing radiation and surgical platforms.

Key Market Players

The U.S. Oncology Devices Competitive Landscape is moderately consolidated in radiation therapy, robotic surgery, imaging, and several procedural categories, but remains fragmented across biopsy, ablation, navigation, localization, and supportive technologies. Large medtech companies compete through broad platforms, capital financing, service networks, software integration, and enterprise contracts. Specialized companies compete through clinical differentiation in a particular tumor type or treatment modality. The market supports both models because oncology pathways require many devices and because a focused product can create substantial value when it improves access, precision, or treatment economics.

Competition is increasingly ecosystem-based. Radiation therapy vendors compete on imaging, treatment delivery, planning, oncology information systems, adaptive workflow, and service. Surgical companies compete on robotic platforms, visualization, instruments, energy, stapling, and procedure support. Interventional oncology companies compete on generators, probes, navigation, embolization, and evidence. Imaging companies compete on modality performance and integration with biopsy, surgery, or radiation. Over the forecast period, market share will be influenced by FDA authorizations, clinical evidence, reimbursement support, cybersecurity, supply reliability, training capacity, and the ability to demonstrate measurable workflow improvement.

Some of the key players in the U.S. Oncology Devices industry are

Siemens Healthineers and Varian,
Elekta,
Accuray Incorporated,
GE HealthCare,
Philips Healthcare,
Canon Medical Systems USA,
Hologic,
BD,
Medtronic,
Boston Scientific Corporation,
Johnson & Johnson MedTech,
Intuitive Surgical,
Stryker,
Olympus Corporation of the Americas,
FUJIFILM Healthcare Americas,
KARL STORZ Endoscopy-America,
AngioDynamics,
Merit Medical Systems,
IceCure Medical,
Novocure,
IBA,
CQ Medical,
Profound Medical,
INSIGHTEC,
Brainlab.

Siemens Healthineers through Varian, Elekta, and Accuray are the most visible competitors in external beam radiation and radiosurgery. GE HealthCare, Philips, Canon Medical, and Brainlab influence oncology imaging, guidance, navigation, and workflow integration. Intuitive Surgical, Johnson & Johnson MedTech, Medtronic, Stryker, Olympus, FUJIFILM, and KARL STORZ compete across minimally invasive cancer surgery, endoscopy, energy, and visualization. Hologic and BD have strong positions in breast biopsy and tissue acquisition. AngioDynamics, Merit Medical, IceCure, Profound Medical, and INSIGHTEC participate in interventional oncology and focal therapy. Novocure is differentiated through tumor treating fields, while IBA has a major presence in proton therapy and dosimetry-related technology.

The strongest competitive positions will be built by companies that combine differentiated clinical performance with implementation discipline. U.S. buyers will reward systems that improve room utilization, reduce manual steps, support multi-site standardization, and provide resilient service. Specialized companies can win share when they address an underserved cancer population or deliver an intervention that avoids hospitalization or open surgery. However, they must invest in physician training, patient selection, payer engagement, and real-world evidence to convert clinical interest into routine use.

Recent Developments

Recent developments in the U.S. Oncology Devices Market show that innovation is moving beyond conventional hospital-based treatment toward adaptive, minimally invasive, and distributed care. In February 2026, the FDA approved Optune Pax for adults with locally advanced pancreatic cancer. The portable device delivers tumor treating fields to the abdomen and represents a significant expansion of non-invasive device therapy into a cancer type with limited treatment options. The approval also demonstrates the growing role of home-compatible oncology devices and recurring service models.

In early 2026, the U.S. market also advanced in local breast tumor treatment through authorization of the ProSense cryoablation system for selected patients age 70 and older with biologically low-risk tumors of 1.5 centimeters or less who receive endocrine therapy. This development is strategically important because it introduces a device-based local treatment option for a narrowly defined population that may not be suitable for surgery. It also strengthens the broader commercial case for image-guided cryoablation in outpatient oncology.

Radiation oncology manufacturers continued to emphasize adaptive precision and workflow automation. Elekta received U.S. FDA 510(k) clearance for the Elekta Evo linear accelerator in 2026, adding a new platform focused on imaging and workflow efficiency. Varian continued to expand imaging and software options across its treatment systems, while the broader market increased attention to high-quality onboard imaging, surface guidance, motion management, and AI-supported planning. These upgrades are commercially relevant because they can extend the life and productivity of installed treatment rooms.

The FDA oncology device pipeline remains broad. In 2023, the agency authorized 118 oncology devices in collaboration with its Oncology Center of Excellence, including 41 radiation oncology and diagnostic imaging devices as well as products for tumor ablation, biopsy, soft-tissue marking, and other applications. The volume and diversity of authorizations illustrate the competitive intensity of the market and the continuing expansion of device roles across the cancer pathway.

Interventional oncology development is also accelerating. Manufacturers are refining cryoablation, microwave ablation, irreversible electroporation, and image-guided access systems for solid tumors. New systems are being designed for minimally invasive, open, or endoscopic use across liver, kidney, prostate, lung, breast, pancreatic, and soft-tissue applications. Commercial adoption is increasingly linked to multidisciplinary treatment protocols and to evidence showing that local therapy improves control, reduces symptoms, or complements systemic treatment.

The competitive landscape is being shaped by partnerships between imaging, radiation therapy, software, and precision oncology companies. Collaboration around theranostics, advanced imaging, AI, and treatment planning is intended to connect diagnosis with therapy selection and response assessment. Health systems are also signing multi-year technology and service agreements to modernize radiation oncology networks rather than purchasing one system at a time. This favors vendors with broad portfolios and dependable implementation capacity, while creating partnership opportunities for specialized innovators.

Conclusion

The U.S. Oncology Devices Market Size & Share is positioned for sustained expansion from USD 44.85 billion in 2025 to USD 112.17 billion by 2035, supported by a 9.60% CAGR during the forecast period. The market’s long-term strength is grounded in more than two million new cancer diagnoses per year, an aging population, a growing survivor base, and the increasing device intensity of precision oncology. Unlike markets that depend on a single procedure category, oncology devices benefit from a broad pathway that includes diagnosis, localization, surgery, radiation, ablation, supportive treatment, and ongoing surveillance.

The most attractive growth opportunities will come from adaptive and image-guided radiation therapy, stereotactic treatment, robotic oncology surgery, navigational biopsy, cryoablation and other focal therapies, tumor treating fields, AI-enabled planning, and connected oncology workflow platforms. Mature categories such as conventional linear accelerators, endoscopy, biopsy, and surgical instruments will remain important, but revenue growth will increasingly depend on technologies that improve precision and system economics at the same time.

Regional opportunity will be led by the South because of its population scale and cancer burden, followed by the West’s technology-driven expansion, the Northeast’s high-acuity academic market, and the Midwest’s stable procedure and replacement base. At the state level, California, Florida, Texas, New York, Pennsylvania, Illinois, Ohio, North Carolina, Georgia, New Jersey, Michigan, Massachusetts, Virginia, Washington, and Arizona will remain especially important. Smaller and rural states create a different opportunity centered on distributed capacity, compact platforms, remote planning, and technologies that reduce travel or treatment duration.

For clients evaluating this market, the central strategic question is not whether oncology device demand will grow. The critical questions are which technologies will become embedded in standard pathways, where capital replacement will occur first, how outpatient and home-based care will change the revenue model, and which vendors can demonstrate both clinical benefit and operational value. Companies that combine evidence, workflow integration, service reliability, reimbursement support, and scalable implementation will define the next decade of the U.S. oncology devices industry.

TABLE OF CONTENT

1. U.S. Oncology Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.2.1. Devices Included in the Market Scope
1.2.2. Devices and Services Excluded from the Market Scope
1.2.3. Geographic Coverage
1.2.4. Historical, Base Year, and Forecast Period
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Bottom-Up Market Estimation
1.3.6. Top-Down Market Validation
1.3.7. Procedure-Volume and Installed-Base Modeling
1.3.8. Analytical Frameworks & Forecasting Models
1.3.9. Data Triangulation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Oncology Device Manufacturers
1.6.2. Component and Contract Manufacturing Suppliers
1.6.3. Cancer Hospitals and Integrated Delivery Networks
1.6.4. Comprehensive and Academic Cancer Centers
1.6.5. Radiation Oncology Practices
1.6.6. Surgical Oncology and Interventional Oncology Departments
1.6.7. Diagnostic Imaging and Pathology Providers
1.6.8. Ambulatory Surgery Centers and Outpatient Cancer Facilities
1.6.9. Group Purchasing Organizations and Distributors
1.6.10. Payers, Regulators, and Clinical Decision-Makers

What this section provides: This section defines the U.S. oncology devices market boundary, included technologies, study period, research methodology, assumptions, and stakeholder ecosystem so clients understand how the market is measured, segmented, and validated.

2. U.S. Oncology Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size and CAGR Summary
2.8. Dominant Product Category
2.9. Fastest-Growing Product Category
2.10. Dominant Cancer Application
2.11. Fastest-Growing Technology Platform
2.12. Leading End-User Category
2.13. Largest Regional Market
2.14. Fastest-Growing Regional Market
2.15. High-Growth Opportunity Areas
2.15.1. Image-Guided Radiation Therapy
2.15.2. Adaptive and AI-Assisted Radiation Oncology
2.15.3. Robotic and Minimally Invasive Cancer Surgery
2.15.4. Percutaneous Tumor Ablation
2.15.5. Proton and Particle Therapy
2.15.6. Tumor Treating Fields
2.15.7. Advanced Cancer Screening and Biopsy Systems

What this section provides: This section gives decision-makers a concise view of market size, historical performance, forecast growth, major demand pockets, competitive intensity, leading technologies, regional opportunities, and priority investment areas.

3. U.S. Oncology Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Cancer Incidence and Survivorship Burden
3.1.2. Aging Population and Increasing Multimorbidity
3.1.3. Expansion of Cancer Screening and Earlier Diagnosis
3.1.4. Growth in Image-Guided and Minimally Invasive Oncology Procedures
3.1.5. Replacement and Modernization of Radiation Oncology Infrastructure
3.1.6. Increasing Use of Robotic and Navigation-Assisted Cancer Surgery
3.1.7. Growth of Interventional Oncology and Outpatient Tumor Ablation
3.1.8. Expansion of Comprehensive and Community Cancer Networks
3.1.9. Rising Demand for Precision Treatment Planning
3.1.10. Integration of AI into Oncology Imaging and Treatment Workflows
3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Advanced Oncology Systems
3.2.2. Long Hospital Budgeting and Procurement Cycles
3.2.3. Reimbursement Pressure and Value Analysis Scrutiny
3.2.4. Radiation Oncology Workforce and Medical Physics Constraints
3.2.5. Complex Installation, Shielding, and Facility Requirements
3.2.6. Product Recall, Cybersecurity, and Patient-Safety Risks
3.2.7. Rural and Community-Level Access Disparities
3.2.8. Limited Procedure Volumes for Selected Premium Technologies
3.3. Opportunities and Their Impact Analysis
3.3.1. Adaptive Radiation Therapy Adoption
3.3.2. AI-Assisted Treatment Planning and Image Segmentation
3.3.3. Expansion of Stereotactic Radiosurgery and Body Radiotherapy
3.3.4. Growth of Proton Therapy and Compact Particle Systems
3.3.5. Percutaneous Ablation for Medically Inoperable Patients
3.3.6. Robotics in Thoracic, Colorectal, Urologic, and Gynecologic Oncology
3.3.7. Tumor Treating Fields for Additional Cancer Indications
3.3.8. Mobile, Modular, and Distributed Oncology Technologies
3.3.9. Remote Treatment Planning and Cloud-Connected Oncology Workflows
3.3.10. Equipment-as-a-Service and Managed Technology Models
3.4. Challenges and Their Impact Analysis
3.4.1. Demonstrating Incremental Clinical Value
3.4.2. Achieving Sufficient Capital Utilization
3.4.3. Interoperability Across Imaging, Planning, and Treatment Platforms
3.4.4. Standardizing Clinical Evidence Across Cancer Types
3.4.5. Managing Consumable and Service Contract Costs
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.6.1. Procedure Time and Room Turnover
3.6.2. Patient Throughput and Capacity Utilization
3.6.3. Length of Stay and Site-of-Care Economics
3.6.4. Staffing and Training Requirements
3.6.5. Capital Depreciation and Service Economics
3.7. Hospital Capital Procurement Behavior Analysis
3.7.1. Capital Committee Approval Criteria
3.7.2. Clinical Champion Influence
3.7.3. Return-on-Investment Requirements
3.7.4. Total Cost of Ownership Assessment
3.7.5. Technology Replacement Cycles
3.7.6. Multi-Year Capital Planning
3.8. Oncology Device Adoption Curve Analysis

What this section provides: This section explains the epidemiological, clinical, reimbursement, capital-planning, and operational forces shaping oncology-device demand, helping clients evaluate growth opportunities, adoption barriers, and execution risks.

4. U.S. Oncology Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.3.1. Capital Equipment Pricing
4.3.2. Disposable and Procedure-Based Device Pricing
4.3.3. Service and Maintenance Contract Pricing
4.3.4. Software Subscription and Licensing Models
4.4. Value Chain & Supply Chain Analysis
4.4.1. Raw Materials and Electronic Components
4.4.2. Imaging, Radiation, and Robotic System Manufacturing
4.4.3. Sterile Disposable Manufacturing
4.4.4. Distribution and Installation
4.4.5. Clinical Training and Technical Support
4.4.6. Maintenance, Upgrades, and Replacement
4.5. Impact of Digitalization and Connected Oncology
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. Class I, II, and III Device Considerations
4.7.2. 510(k) Premarket Notification
4.7.3. Premarket Approval
4.7.4. De Novo Classification
4.7.5. Breakthrough Devices Program
4.7.6. Software as a Medical Device
4.7.7. Quality System and Post-Market Surveillance Requirements
4.8. CMS Reimbursement and Coverage Landscape
4.8.1. Inpatient Prospective Payment System
4.8.2. Hospital Outpatient Prospective Payment System
4.8.3. Physician Fee Schedule
4.8.4. Ambulatory Surgical Center Reimbursement
4.8.5. Local and National Coverage Determinations
4.9. Import/Export Restrictions & Tariff Impact
4.10. Government Initiatives and Cancer-Control Programs
4.11. Impact of Escalating Geopolitical Tensions
4.12. Hospital Value Analysis Committee Decision Framework
4.13. Health Technology Assessment and Evidence Requirements
4.14. Sustainability and Oncology Equipment Lifecycle Management

What this section provides: This section gives clients a complete view of the external market environment, including regulation, reimbursement, pricing, supply chains, technology adoption, legal considerations, capital procurement, and lifecycle economics.

5. U.S. Oncology Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
5.2. Cancer Diagnostic and Screening Devices
5.2.1. Diagnostic Imaging Systems
5.2.1.1. Computed Tomography Systems
5.2.1.2. Magnetic Resonance Imaging Systems
5.2.1.3. Positron Emission Tomography Systems
5.2.1.4. Single-Photon Emission Computed Tomography Systems
5.2.1.5. Ultrasound and Elastography Systems
5.2.1.6. Mammography and Digital Breast Tomosynthesis Systems
5.2.2. Biopsy and Tissue Acquisition Devices
5.2.2.1. Core Needle Biopsy Devices
5.2.2.2. Fine-Needle Aspiration Devices
5.2.2.3. Vacuum-Assisted Breast Biopsy Systems
5.2.2.4. Image-Guided Biopsy Systems
5.2.2.5. Endoscopic Biopsy Devices
5.2.3. Endoscopic Cancer Detection Systems
5.2.4. Digital Pathology and Slide-Scanning Systems
5.2.5. Image-Guided Localization Devices
5.3. Radiation Therapy Devices
5.3.1. Linear Accelerators
5.3.2. Image-Guided Radiation Therapy Systems
5.3.3. Intensity-Modulated Radiation Therapy Systems
5.3.4. Stereotactic Radiosurgery Systems
5.3.5. Stereotactic Body Radiation Therapy Systems
5.3.6. Brachytherapy Systems
5.3.7. Proton Therapy Systems
5.3.8. Particle and Heavy-Ion Therapy Systems
5.3.9. Radiation Treatment Planning Systems
5.3.10. Dosimetry and Quality-Assurance Devices
5.3.11. Patient Positioning and Immobilization Devices
5.4. Surgical Oncology Devices
5.4.1. Robotic-Assisted Surgical Systems
5.4.2. Laparoscopic and Endoscopic Surgical Devices
5.4.3. Electrosurgical and Advanced Energy Devices
5.4.4. Surgical Navigation Systems
5.4.5. Intraoperative Imaging Systems
5.4.6. Tumor Localization and Margin Assessment Devices
5.4.7. Surgical Stapling and Tissue-Sealing Devices
5.4.8. Smoke Evacuation and Surgical Safety Systems
5.5. Tumor Ablation and Interventional Oncology Devices
5.5.1. Radiofrequency Ablation Systems
5.5.2. Microwave Ablation Systems
5.5.3. Cryoablation Systems
5.5.4. High-Intensity Focused Ultrasound Systems
5.5.5. Irreversible Electroporation Systems
5.5.6. Laser Ablation Systems
5.5.7. Transarterial Embolization Devices
5.5.8. Radioembolization Delivery Devices
5.5.9. Image-Guided Interventional Oncology Accessories
5.6. Oncology Drug-Delivery and Support Devices
5.6.1. Infusion Pumps
5.6.2. Implantable Ports
5.6.3. Central Venous Access Devices
5.6.4. Ambulatory Infusion Systems
5.6.5. Closed-System Transfer Devices
5.6.6. Extravasation Detection and Prevention Devices
5.7. Tumor Treating Fields and Emerging Therapeutic Devices
5.7.1. Tumor Treating Fields Systems
5.7.2. Photodynamic Therapy Devices
5.7.3. Electrochemotherapy Systems
5.7.4. Hyperthermia Therapy Systems
5.7.5. Wearable and Home-Based Oncology Treatment Devices

What this section provides: This section identifies which oncology-device categories are expected to generate the greatest revenue contribution and strongest growth through 2035, while distinguishing capital systems, procedure-based devices, consumables, software, and emerging therapies.

6. U.S. Oncology Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
6.2. Breast Cancer
6.2.1. Screening and Diagnostic Imaging
6.2.2. Image-Guided Biopsy
6.2.3. Breast-Conserving Surgery
6.2.4. Radiation Therapy
6.2.5. Tumor Localization and Margin Assessment
6.3. Lung Cancer
6.3.1. Low-Dose CT Screening
6.3.2. Bronchoscopy and Navigational Biopsy
6.3.3. Thoracic Robotic Surgery
6.3.4. Stereotactic Body Radiation Therapy
6.3.5. Percutaneous Tumor Ablation
6.4. Prostate Cancer
6.4.1. MRI and Ultrasound-Guided Diagnosis
6.4.2. Fusion-Guided Biopsy
6.4.3. Robotic Prostatectomy
6.4.4. Radiation Therapy and Brachytherapy
6.4.5. Focal Ablation
6.5. Colorectal Cancer
6.5.1. Colonoscopy and Endoscopic Detection
6.5.2. Endoscopic Resection Devices
6.5.3. Laparoscopic and Robotic Surgery
6.5.4. Radiation Therapy for Rectal Cancer
6.5.5. Liver Metastasis Ablation and Embolization
6.6. Gynecologic Cancer
6.6.1. Cervical Cancer Screening and Colposcopy
6.6.2. Robotic and Laparoscopic Surgery
6.6.3. Brachytherapy
6.6.4. Radiation Therapy
6.6.5. Image-Guided Biopsy and Ablation
6.7. Liver, Pancreatic, and Biliary Cancers
6.7.1. Image-Guided Biopsy
6.7.2. Thermal Ablation
6.7.3. Irreversible Electroporation
6.7.4. Embolization and Radioembolization
6.7.5. Stereotactic Radiation Therapy
6.7.6. Tumor Treating Fields
6.8. Brain and Central Nervous System Tumors
6.8.1. Intraoperative Imaging
6.8.2. Surgical Navigation
6.8.3. Stereotactic Radiosurgery
6.8.4. Laser Interstitial Thermal Therapy
6.8.5. Tumor Treating Fields
6.9. Head and Neck Cancer
6.9.1. Endoscopic Diagnostic Devices
6.9.2. Robotic and Laser Surgery
6.9.3. Radiation Therapy
6.9.4. Brachytherapy
6.10. Kidney and Bladder Cancer
6.10.1. Cystoscopy and Diagnostic Imaging
6.10.2. Robotic Surgery
6.10.3. Cryoablation and Thermal Ablation
6.10.4. Radiation Therapy
6.11. Skin Cancer and Melanoma
6.11.1. Dermoscopy and Imaging Devices
6.11.2. Biopsy Devices
6.11.3. Surgical and Margin-Assessment Devices
6.11.4. Radiation and Photodynamic Therapy Devices
6.12. Other Cancer Applications
6.12.1. Bone and Soft-Tissue Tumors
6.12.2. Esophageal and Gastric Cancer
6.12.3. Thyroid Cancer
6.12.4. Pediatric Cancer
6.12.5. Hematologic Malignancies and Supportive Device Use

What this section provides: This section helps clients understand oncology-device demand by cancer type and clinical use case, enabling prioritization of indications with strong screening volumes, procedure growth, reimbursement relevance, and technology adoption.

7. U.S. Oncology Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
7.2. Hospitals and Integrated Health Systems
7.2.1. Tertiary and Quaternary Hospitals
7.2.2. Community Hospitals
7.2.3. Multi-Hospital Integrated Delivery Networks
7.3. Comprehensive and Academic Cancer Centers
7.3.1. NCI-Designated Cancer Centers
7.3.2. University-Affiliated Cancer Programs
7.3.3. Clinical Trial and Research Centers
7.4. Radiation Oncology Centers
7.4.1. Hospital-Owned Radiation Centers
7.4.2. Independent Radiation Oncology Practices
7.4.3. Proton Therapy Centers
7.4.4. Stereotactic Radiosurgery Centers
7.5. Ambulatory Surgery Centers and Outpatient Cancer Facilities
7.5.1. Multispecialty Ambulatory Surgery Centers
7.5.2. Oncology-Focused Surgery Centers
7.5.3. Office-Based Interventional Oncology Facilities
7.6. Diagnostic Imaging and Screening Centers
7.6.1. Breast Imaging Centers
7.6.2. PET/CT and Nuclear Medicine Centers
7.6.3. Independent Diagnostic Testing Facilities
7.6.4. Mobile Cancer Screening Providers
7.7. Pathology and Diagnostic Laboratories
7.7.1. Hospital Pathology Laboratories
7.7.2. Independent Pathology Laboratories
7.7.3. Digital Pathology Networks
7.8. Specialty Oncology Clinics and Physician Practices
7.8.1. Medical Oncology Practices
7.8.2. Urology Practices
7.8.3. Gastroenterology Practices
7.8.4. Pulmonology and Thoracic Oncology Practices
7.8.5. Dermatology Practices
7.9. Home Healthcare and Remote Oncology Providers
7.9.1. Home Infusion Providers
7.9.2. Remote Treatment Monitoring Providers
7.9.3. Wearable Oncology Therapy Providers

What this section provides: This section explains which care settings and customer groups are expected to drive capital purchasing, procedure adoption, disposable utilization, treatment capacity, and recurring oncology-device demand.

8. U.S. Oncology Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
8.2. Radiation-Based Technologies
8.2.1. Photon Radiation Systems
8.2.2. Brachytherapy Technologies
8.2.3. Proton and Particle Therapy Technologies
8.2.4. Stereotactic Radiation Technologies
8.2.5. Adaptive Radiation Technologies
8.3. Imaging-Guided Technologies
8.3.1. CT-Guided Oncology Procedures
8.3.2. MRI-Guided Oncology Procedures
8.3.3. PET-Guided Oncology Workflows
8.3.4. Ultrasound-Guided Oncology Procedures
8.3.5. Fluoroscopy and Cone-Beam CT Guidance
8.4. Robotic and Navigation-Assisted Technologies
8.4.1. Robotic Surgical Systems
8.4.2. Robotic Bronchoscopy Systems
8.4.3. Surgical Navigation Systems
8.4.4. Electromagnetic Navigation Systems
8.4.5. Robotic Radiation Delivery Systems
8.5. Energy-Based Tumor Treatment Technologies
8.5.1. Radiofrequency Energy
8.5.2. Microwave Energy
8.5.3. Cryogenic Energy
8.5.4. Focused Ultrasound Energy
8.5.5. Laser Energy
8.5.6. Electrical Field and Electroporation Technologies
8.5.7. Photodynamic Technologies
8.6. Software-Enabled and AI-Assisted Technologies
8.6.1. AI-Assisted Cancer Detection
8.6.2. Automated Image Segmentation
8.6.3. Radiation Treatment Planning Software
8.6.4. Adaptive Treatment Software
8.6.5. Surgical Planning and Navigation Software
8.6.6. Oncology Workflow and Analytics Platforms
8.6.7. Remote Monitoring and Cloud Connectivity
8.7. Implantable, Wearable, and Disposable Technologies
8.7.1. Implantable Access Devices
8.7.2. Wearable Tumor Treating Fields Devices
8.7.3. Disposable Biopsy and Ablation Devices
8.7.4. Single-Use Endoscopic Oncology Devices
8.7.5. Smart Infusion and Drug-Delivery Devices

What this section provides: This section evaluates the core technology platforms reshaping cancer diagnosis and treatment, including radiation systems, imaging guidance, robotic assistance, tumor ablation, AI software, implantables, wearables, and disposable devices.

9. U.S. Oncology Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
9.2. Direct Hospital and Cancer Center Procurement
9.2.1. Capital Equipment Purchases
9.2.2. Procedure-Based Disposable Contracts
9.2.3. Service and Maintenance Agreements
9.3. Integrated Delivery Network Enterprise Contracts
9.3.1. Multi-Facility Standardization
9.3.2. Enterprise Software and Imaging Agreements
9.3.3. Strategic Technology Partnerships
9.4. Group Purchasing Organization Contracts
9.4.1. National GPO Agreements
9.4.2. Regional GPO Agreements
9.4.3. Aggregated Purchasing and Tiered Pricing
9.5. Distributor and Specialty Supplier Sales
9.5.1. National Medical Device Distributors
9.5.2. Specialty Oncology Distributors
9.5.3. Radiation Oncology Equipment Resellers
9.6. Ambulatory and Physician-Practice Procurement
9.6.1. Ambulatory Surgery Center Purchasing
9.6.2. Independent Oncology Practice Purchasing
9.6.3. Office-Based Laboratory Purchasing
9.7. Leasing, Managed Service, and Equipment-as-a-Service Models
9.7.1. Capital Leasing
9.7.2. Managed Equipment Services
9.7.3. Pay-Per-Procedure Agreements
9.7.4. Subscription-Based Software Procurement

What this section provides: This section helps clients understand how oncology devices are purchased in the U.S., including direct capital procurement, IDN standardization, GPO influence, distributor sales, outpatient purchasing, leasing, and managed-service models.

10. U.S. Oncology Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Cancer Incidence and Screening Analysis
10.1.4. Regional Oncology Procedure Volume Analysis
10.1.5. Regional Hospital and Cancer Center Infrastructure Analysis
10.1.6. Regional Radiation Oncology Installed-Base Analysis
10.1.7. Regional Reimbursement and Procurement Dynamics
10.1.8. Regional Technology-Adoption and Replacement-Cycle Analysis

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Oncology Device Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Oncology Device Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Oncology Device Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Oncology Device Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level intelligence across all 50 states, helping clients identify cancer-care hubs, oncology procedure concentrations, screening demand, installed-equipment opportunities, replacement cycles, reimbursement differences, and state-level commercial priorities.

11. U.S. Oncology Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.1.1. Market Share by Revenue
11.1.2. Market Share by Product Category
11.1.3. Market Share by Installed Base
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players
11.3. Competitive Benchmarking
11.3.1. Product Portfolio Breadth
11.3.2. Technology Differentiation
11.3.3. U.S. Commercial Reach
11.3.4. Clinical Evidence Strength
11.3.5. Regulatory Pipeline
11.3.6. Hospital Contracting Capabilities
11.3.7. Service and Maintenance Infrastructure
11.4. Company Profiles
11.4.1. Siemens Healthineers
11.4.2. Varian Medical Systems
11.4.3. GE HealthCare
11.4.4. Elekta
11.4.5. Accuray Incorporated
11.4.6. Koninklijke Philips N.V.
11.4.7. Canon Medical Systems USA
11.4.8. Intuitive Surgical
11.4.9. Medtronic
11.4.10. Johnson & Johnson MedTech
11.4.11. Boston Scientific Corporation
11.4.12. Stryker Corporation
11.4.13. Becton, Dickinson and Company
11.4.14. Hologic
11.4.15. Fujifilm Holdings Corporation
11.4.16. Olympus Corporation
11.4.17. AngioDynamics
11.4.18. Merit Medical Systems
11.4.19. Novocure
11.4.20. Ion Beam Applications
11.4.21. Hitachi High-Tech America
11.4.22. EDAP TMS
11.4.23. IceCure Medical
11.4.24. Profound Medical
11.4.25. Delcath Systems

Note: Each company profile will include company overview, oncology-device portfolio, U.S. market strategy, financial positioning, installed base, clinical pipeline, regulatory activity, partnerships, acquisitions, product launches, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, innovation direction, installed-base intelligence, commercial strategy, and detailed profiles of major oncology-device companies.

12. U.S. Oncology Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Adaptive Radiation Therapy
12.2.2. AI-Assisted Cancer Detection and Treatment Planning
12.2.3. MRI-Guided Radiation Therapy
12.2.4. Compact Proton Therapy Systems
12.2.5. Robotic Bronchoscopy and Navigation
12.2.6. Robotic-Assisted Cancer Surgery
12.2.7. Image-Guided Percutaneous Tumor Ablation
12.2.8. Tumor Treating Fields
12.2.9. Digital Pathology and Computational Oncology
12.2.10. Remote and Home-Based Oncology Technologies
12.3. Emerging Business Trends
12.3.1. Platform-Based Oncology Ecosystems
12.3.2. Vendor Consolidation and Portfolio Bundling
12.3.3. Managed Service Agreements
12.3.4. Equipment-as-a-Service Models
12.3.5. Hospital Network Standardization
12.3.6. Data-Driven Value-Based Contracting
12.3.7. Expansion of Outpatient Oncology Procedures
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.5.1. High-Growth and High-Attractiveness Technologies
12.5.2. Moderate-Growth and Defensible Technologies
12.5.3. Mature and Replacement-Driven Technologies
12.6. Market Entry Timing Analysis
12.7. Technology Adoption Forecast
12.8. Capital Replacement Cycle Outlook

What this section provides: This section prepares clients for future technology shifts, changing site-of-care models, capital replacement cycles, market-structure changes, investment opportunities, and alternative adoption scenarios through 2035.

13. U.S. Oncology Devices Market: Strategic Recommendations

13.1. Recommendations for Oncology Device Manufacturers
13.1.1. Portfolio Prioritization
13.1.2. Clinical Evidence Development
13.1.3. Hospital Economic Value Demonstration
13.1.4. Service and Training Differentiation
13.2. Recommendations for Hospitals and Cancer Centers
13.2.1. Capital Planning
13.2.2. Installed-Base Optimization
13.2.3. Procedure-Capacity Expansion
13.2.4. Vendor Standardization
13.3. Recommendations for Investors and Private Equity Firms
13.3.1. High-Growth Technology Screening
13.3.2. Platform Consolidation Opportunities
13.3.3. Recurring-Revenue Business Models
13.3.4. Regulatory and Reimbursement Risk Assessment
13.4. Recommendations for Distributors and Channel Partners
13.4.1. Specialty Portfolio Development
13.4.2. Regional Coverage Expansion
13.4.3. Clinical Support Capabilities
13.5. Recommendations for New Entrants and Startups
13.5.1. Unmet Clinical Need Identification
13.5.2. FDA Pathway Planning
13.5.3. Evidence and Reimbursement Strategy
13.5.4. Strategic Partnership Development
13.6. Go-to-Market Strategy Considerations
13.6.1. Academic Cancer Center Entry
13.6.2. Community Oncology Expansion
13.6.3. Key Opinion Leader Engagement
13.6.4. Regional Commercialization Strategy
13.6.5. GPO and IDN Contracting
13.7. Product Positioning and Portfolio Expansion Guidance
13.8. Pricing and Contracting Recommendations
13.9. Mergers, Acquisitions, and Partnership Opportunities

What this section provides: This section converts market intelligence into actionable strategy for growth planning, product positioning, clinical evidence generation, channel expansion, capital procurement, investment decisions, and competitive differentiation.

14. U.S. Oncology Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Market Estimation Limitation
14.5. Legal Disclaimer
14.6. Third-Party Data Disclaimer
14.7. Company and Product Information Disclaimer
14.8. Regulatory and Reimbursement Disclaimer
14.9. Currency and Rounding Disclaimer

What this section provides: This section clarifies the report’s scope limitations, forecasting assumptions, legal boundaries, data-use conditions, company-information limitations, and regulatory and reimbursement considerations.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Oncology Devices Market: Market Definition and Scope
TABLE 3: U.S. Oncology Devices Market: Research Methodology Framework
TABLE 4: U.S. Oncology Devices Market: Market Estimation and Data Triangulation Framework
TABLE 5: U.S. Oncology Devices Market: Key Assumptions
TABLE 6: U.S. Oncology Devices Market: Market Ecosystem Overview
TABLE 7: U.S. Oncology Devices Market: Stakeholder Analysis
TABLE 8: U.S. Oncology Devices Market: Executive Summary Snapshot, 2025
TABLE 9: U.S. Oncology Devices Market: Analyst Viewpoint Summary
TABLE 10: U.S. Oncology Devices Market: Market Attractiveness Index
TABLE 11: U.S. Oncology Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 12: U.S. Oncology Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Oncology Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Oncology Devices Market: High-Growth Opportunity Areas
TABLE 15: U.S. Oncology Devices Market: Drivers; Impact Analysis
TABLE 16: U.S. Oncology Devices Market: Restraints; Impact Analysis
TABLE 17: U.S. Oncology Devices Market: Opportunities; Impact Analysis
TABLE 18: U.S. Oncology Devices Market: Challenges; Impact Analysis
TABLE 19: U.S. Oncology Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 20: U.S. Oncology Devices Market: Clinical Workflow Economics Matrix
TABLE 21: U.S. Oncology Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 22: U.S. Oncology Devices Market: Oncology Device Adoption Curve Analysis
TABLE 23: U.S. Oncology Devices Market: PESTEL Analysis
TABLE 24: U.S. Oncology Devices Market: Porter’s Five Forces Analysis
TABLE 25: U.S. Oncology Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 26: U.S. Oncology Devices Market: Value Chain Analysis
TABLE 27: U.S. Oncology Devices Market: Supply Chain Analysis
TABLE 28: U.S. Oncology Devices Market: Digitalization and Connected Oncology Impact
TABLE 29: U.S. Oncology Devices Market: Application & Innovation Landscape
TABLE 30: U.S. Oncology Devices Market: FDA Regulatory Framework Analysis
TABLE 31: U.S. Oncology Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 32: U.S. Oncology Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 33: U.S. Oncology Devices Market: Government Initiatives and Cancer-Control Programs
TABLE 34: U.S. Oncology Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 35: U.S. Oncology Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 36: U.S. Oncology Devices Market: Health Technology Assessment and Evidence Requirements
TABLE 37: U.S. Oncology Devices Market: Sustainability and Oncology Equipment Lifecycle Management
TABLE 38: U.S. Oncology Devices Market: Product Category Snapshot, 2025
TABLE 39: Segment Dashboard; Definition and Scope, by Product Category
TABLE 40: U.S. Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 41: U.S. Oncology Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 42: U.S. Oncology Devices Market: Cancer Diagnostic and Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: U.S. Oncology Devices Market: Radiation Therapy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: U.S. Oncology Devices Market: Surgical Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. Oncology Devices Market: Tumor Ablation and Interventional Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Oncology Devices Market: Oncology Drug-Delivery and Support Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Oncology Devices Market: Tumor Treating Fields and Emerging Therapeutic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Oncology Devices Market: Application Snapshot, 2025
TABLE 49: Segment Dashboard; Definition and Scope, by Application
TABLE 50: U.S. Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 51: U.S. Oncology Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 52: U.S. Oncology Devices Market: Breast Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. Oncology Devices Market: Lung Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Oncology Devices Market: Prostate Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Oncology Devices Market: Colorectal Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Oncology Devices Market: Gynecologic Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Oncology Devices Market: Liver, Pancreatic, and Biliary Cancers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Oncology Devices Market: Brain and Central Nervous System Tumors Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. Oncology Devices Market: Head and Neck Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Oncology Devices Market: Kidney and Bladder Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. Oncology Devices Market: Skin Cancer and Melanoma Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. Oncology Devices Market: Other Cancer Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Oncology Devices Market: End User Snapshot, 2025
TABLE 64: Segment Dashboard; Definition and Scope, by End User
TABLE 65: U.S. Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 66: U.S. Oncology Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 67: U.S. Oncology Devices Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. Oncology Devices Market: Comprehensive and Academic Cancer Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. Oncology Devices Market: Radiation Oncology Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. Oncology Devices Market: Ambulatory Surgery Centers and Outpatient Cancer Facilities Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. Oncology Devices Market: Diagnostic Imaging and Screening Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. Oncology Devices Market: Pathology and Diagnostic Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Oncology Devices Market: Specialty Oncology Clinics and Physician Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Oncology Devices Market: Home Healthcare and Remote Oncology Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Oncology Devices Market: Technology Type Snapshot, 2025
TABLE 76: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 77: U.S. Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 78: U.S. Oncology Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 79: U.S. Oncology Devices Market: Radiation-Based Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: U.S. Oncology Devices Market: Imaging-Guided Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. Oncology Devices Market: Robotic and Navigation-Assisted Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. Oncology Devices Market: Energy-Based Tumor Treatment Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. Oncology Devices Market: Software-Enabled and AI-Assisted Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. Oncology Devices Market: Implantable, Wearable, and Disposable Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: U.S. Oncology Devices Market: Procurement Channel Snapshot, 2025
TABLE 86: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 87: U.S. Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 88: U.S. Oncology Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 89: U.S. Oncology Devices Market: Direct Hospital and Cancer Center Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 90: U.S. Oncology Devices Market: Integrated Delivery Network Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 91: U.S. Oncology Devices Market: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 92: U.S. Oncology Devices Market: Distributor and Specialty Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 93: U.S. Oncology Devices Market: Ambulatory and Physician-Practice Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 94: U.S. Oncology Devices Market: Leasing, Managed Service, and Equipment-as-a-Service Models Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 95: U.S. Oncology Devices Market: Regional Snapshot, 2025
TABLE 96: Segment Dashboard; Definition and Scope, by Region
TABLE 97: U.S. Oncology Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 98: U.S. Oncology Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 99: U.S. Oncology Devices Market: Regional Cancer Incidence and Screening Analysis
TABLE 100: U.S. Oncology Devices Market: Regional Oncology Procedure Volume and Infrastructure Analysis
TABLE 101: West Region U.S. Oncology Devices Market: Regional Overview and Trends
TABLE 102: West Region U.S. Oncology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 103: West Region U.S. Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 104: West Region U.S. Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 105: West Region U.S. Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 106: West Region U.S. Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 107: West Region U.S. Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 108: West Region U.S. Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 109: California Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 110: California Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 111: California Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 112: California Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 113: California Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 114: Washington Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 115: Washington Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 116: Washington Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 117: Washington Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 118: Washington Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 119: Arizona Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 120: Arizona Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 121: Arizona Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 122: Arizona Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 123: Arizona Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 124: Colorado Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 125: Colorado Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 126: Colorado Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 127: Colorado Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 128: Colorado Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 129: Oregon Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 130: Oregon Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 131: Oregon Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 132: Oregon Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 133: Oregon Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 134: Utah Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 135: Utah Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 136: Utah Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 137: Utah Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 138: Utah Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 139: Nevada Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 140: Nevada Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 141: Nevada Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 142: Nevada Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 143: Nevada Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 144: New Mexico Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 145: New Mexico Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 146: New Mexico Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 147: New Mexico Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 148: New Mexico Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 149: Idaho Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 150: Idaho Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 151: Idaho Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 152: Idaho Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 153: Idaho Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 154: Montana Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 155: Montana Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 156: Montana Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 157: Montana Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 158: Montana Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 159: Wyoming Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 160: Wyoming Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 161: Wyoming Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 162: Wyoming Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 163: Wyoming Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 164: Alaska Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 165: Alaska Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 166: Alaska Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 167: Alaska Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 168: Alaska Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 169: Hawaii Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 170: Hawaii Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 171: Hawaii Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 172: Hawaii Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 173: Hawaii Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 174: Northeast Region U.S. Oncology Devices Market: Regional Overview and Trends
TABLE 175: Northeast Region U.S. Oncology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 176: Northeast Region U.S. Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 177: Northeast Region U.S. Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 178: Northeast Region U.S. Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 179: Northeast Region U.S. Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 180: Northeast Region U.S. Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 181: Northeast Region U.S. Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 182: New York Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 183: New York Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 184: New York Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 185: New York Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 186: New York Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 187: Massachusetts Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 188: Massachusetts Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 189: Massachusetts Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 190: Massachusetts Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 191: Massachusetts Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 192: New Jersey Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 193: New Jersey Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 194: New Jersey Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 195: New Jersey Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 196: New Jersey Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 197: Pennsylvania Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 198: Pennsylvania Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 199: Pennsylvania Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 200: Pennsylvania Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 201: Pennsylvania Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 202: Connecticut Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 203: Connecticut Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 204: Connecticut Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 205: Connecticut Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 206: Connecticut Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 207: Maine Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 208: Maine Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 209: Maine Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 210: Maine Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 211: Maine Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 212: Vermont Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 213: Vermont Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 214: Vermont Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 215: Vermont Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 216: Vermont Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 217: New Hampshire Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 218: New Hampshire Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 219: New Hampshire Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 220: New Hampshire Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 221: New Hampshire Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 222: Rhode Island Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 223: Rhode Island Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 224: Rhode Island Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 225: Rhode Island Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 226: Rhode Island Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 227: Delaware Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 228: Delaware Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 229: Delaware Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 230: Delaware Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 231: Delaware Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 232: South Region U.S. Oncology Devices Market: Regional Overview and Trends
TABLE 233: South Region U.S. Oncology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 234: South Region U.S. Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 235: South Region U.S. Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 236: South Region U.S. Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 237: South Region U.S. Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 238: South Region U.S. Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 239: South Region U.S. Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 240: Texas Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 241: Texas Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 242: Texas Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 243: Texas Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 244: Texas Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 245: Florida Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 246: Florida Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 247: Florida Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 248: Florida Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 249: Florida Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 250: Georgia Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 251: Georgia Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 252: Georgia Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 253: Georgia Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 254: Georgia Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 255: North Carolina Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 256: North Carolina Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 257: North Carolina Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 258: North Carolina Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 259: North Carolina Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 260: Tennessee Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 261: Tennessee Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 262: Tennessee Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 263: Tennessee Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 264: Tennessee Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 265: South Carolina Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 266: South Carolina Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 267: South Carolina Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 268: South Carolina Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 269: South Carolina Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 270: Alabama Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 271: Alabama Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 272: Alabama Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 273: Alabama Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 274: Alabama Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 275: Mississippi Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 276: Mississippi Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 277: Mississippi Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 278: Mississippi Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 279: Mississippi Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 280: Louisiana Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 281: Louisiana Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 282: Louisiana Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 283: Louisiana Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 284: Louisiana Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 285: Arkansas Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 286: Arkansas Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 287: Arkansas Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 288: Arkansas Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 289: Arkansas Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 290: Kentucky Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 291: Kentucky Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 292: Kentucky Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 293: Kentucky Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 294: Kentucky Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 295: Oklahoma Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 296: Oklahoma Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 297: Oklahoma Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 298: Oklahoma Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 299: Oklahoma Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 300: Virginia Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 301: Virginia Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 302: Virginia Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 303: Virginia Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 304: Virginia Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 305: Maryland Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 306: Maryland Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 307: Maryland Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 308: Maryland Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 309: Maryland Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 310: West Virginia Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 311: West Virginia Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 312: West Virginia Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 313: West Virginia Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 314: West Virginia Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 315: Midwest Region U.S. Oncology Devices Market: Regional Overview and Trends
TABLE 316: Midwest Region U.S. Oncology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 317: Midwest Region U.S. Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 318: Midwest Region U.S. Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 319: Midwest Region U.S. Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 320: Midwest Region U.S. Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 321: Midwest Region U.S. Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 322: Midwest Region U.S. Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 323: Illinois Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 324: Illinois Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 325: Illinois Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 326: Illinois Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 327: Illinois Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 328: Ohio Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 329: Ohio Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 330: Ohio Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 331: Ohio Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 332: Ohio Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 333: Michigan Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 334: Michigan Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 335: Michigan Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 336: Michigan Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 337: Michigan Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 338: Minnesota Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 339: Minnesota Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 340: Minnesota Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 341: Minnesota Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 342: Minnesota Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 343: Indiana Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 344: Indiana Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 345: Indiana Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 346: Indiana Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 347: Indiana Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 348: Wisconsin Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 349: Wisconsin Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 350: Wisconsin Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 351: Wisconsin Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 352: Wisconsin Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 353: Missouri Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 354: Missouri Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 355: Missouri Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 356: Missouri Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 357: Missouri Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 358: Iowa Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 359: Iowa Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 360: Iowa Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 361: Iowa Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 362: Iowa Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 363: Kansas Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 364: Kansas Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 365: Kansas Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 366: Kansas Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 367: Kansas Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 368: Nebraska Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 369: Nebraska Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 370: Nebraska Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 371: Nebraska Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 372: Nebraska Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 373: North Dakota Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 374: North Dakota Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 375: North Dakota Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 376: North Dakota Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 377: North Dakota Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 378: South Dakota Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 379: South Dakota Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 380: South Dakota Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 381: South Dakota Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 382: South Dakota Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 383: U.S. Oncology Devices Market: Competitive Landscape Snapshot, 2025
TABLE 384: U.S. Oncology Devices Market: Key Company Market Share Analysis, 2025
TABLE 385: U.S. Oncology Devices Market: Company Positioning Matrix
TABLE 386: U.S. Oncology Devices Market: Competitive Benchmarking of Key Players
TABLE 387: U.S. Oncology Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 388: U.S. Oncology Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 389: Siemens Healthineers: Company Profile
TABLE 390: Varian Medical Systems: Company Profile
TABLE 391: GE HealthCare: Company Profile
TABLE 392: Elekta: Company Profile
TABLE 393: Accuray Incorporated: Company Profile
TABLE 394: Koninklijke Philips N.V.: Company Profile
TABLE 395: Canon Medical Systems USA: Company Profile
TABLE 396: Intuitive Surgical: Company Profile
TABLE 397: Medtronic: Company Profile
TABLE 398: Johnson & Johnson MedTech: Company Profile
TABLE 399: Boston Scientific Corporation: Company Profile
TABLE 400: Stryker Corporation: Company Profile
TABLE 401: Becton, Dickinson and Company: Company Profile
TABLE 402: Hologic: Company Profile
TABLE 403: Fujifilm Holdings Corporation: Company Profile
TABLE 404: Olympus Corporation: Company Profile
TABLE 405: AngioDynamics: Company Profile
TABLE 406: Merit Medical Systems: Company Profile
TABLE 407: Novocure: Company Profile
TABLE 408: Ion Beam Applications: Company Profile
TABLE 409: Hitachi High-Tech America: Company Profile
TABLE 410: EDAP TMS: Company Profile
TABLE 411: IceCure Medical: Company Profile
TABLE 412: Profound Medical: Company Profile
TABLE 413: Delcath Systems: Company Profile
TABLE 414: U.S. Oncology Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 415: U.S. Oncology Devices Market: Disruptive Technologies Impact Matrix
TABLE 416: U.S. Oncology Devices Market: Emerging Business Trends
TABLE 417: U.S. Oncology Devices Market: Business Opportunities for Startups and Existing Players
TABLE 418: U.S. Oncology Devices Market: Investment Prioritization Matrix
TABLE 419: U.S. Oncology Devices Market: Market Entry Timing Analysis
TABLE 420: U.S. Oncology Devices Market: Technology Adoption Forecast
TABLE 421: U.S. Oncology Devices Market: Capital Replacement Cycle Outlook
TABLE 422: U.S. Oncology Devices Market: Strategic Recommendations for Oncology Device Manufacturers
TABLE 423: U.S. Oncology Devices Market: Strategic Recommendations for Hospitals and Cancer Centers
TABLE 424: U.S. Oncology Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 425: U.S. Oncology Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 426: U.S. Oncology Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 427: U.S. Oncology Devices Market: Go-to-Market Strategy Considerations
TABLE 428: U.S. Oncology Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 429: U.S. Oncology Devices Market: Pricing and Contracting Recommendations
TABLE 430: U.S. Oncology Devices Market: Mergers, Acquisitions, and Partnership Opportunities
TABLE 431: U.S. Oncology Devices Market: Scope Limitation
TABLE 432: U.S. Oncology Devices Market: Data Use Limitation
TABLE 433: U.S. Oncology Devices Market: Forecasting Limitation
TABLE 434: U.S. Oncology Devices Market: Market Estimation Limitation
TABLE 435: U.S. Oncology Devices Market: Legal Disclaimer
TABLE 436: U.S. Oncology Devices Market: Third-Party Data Disclaimer
TABLE 437: U.S. Oncology Devices Market: Company and Product Information Disclaimer
TABLE 438: U.S. Oncology Devices Market: Regulatory and Reimbursement Disclaimer
TABLE 439: U.S. Oncology Devices Market: Currency and Rounding Disclaimer

List of Figures

FIGURE 1: U.S. Oncology Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Estimation and Data Triangulation Framework
FIGURE 4: Value Chain Analysis
FIGURE 5: Supply Chain Analysis
FIGURE 6: PESTEL Analysis
FIGURE 7: Porter’s Five Forces Analysis
FIGURE 8: Market Attractiveness Analysis
FIGURE 9: Market Dynamics
FIGURE 10: Innovation & Patent Landscape, 2021–2025
FIGURE 11: Clinical Workflow Economics Framework
FIGURE 12: Hospital Capital Procurement Decision Framework
FIGURE 13: U.S. Oncology Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 14: U.S. Oncology Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 15: U.S. Oncology Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 16: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 17: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 18: Cancer Diagnostic and Screening Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Radiation Therapy Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Surgical Oncology Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Tumor Ablation and Interventional Oncology Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Oncology Drug-Delivery and Support Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Tumor Treating Fields and Emerging Therapeutic Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 25: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Breast Cancer Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Lung Cancer Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Prostate Cancer Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Colorectal Cancer Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Gynecologic Cancer Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Liver, Pancreatic, and Biliary Cancers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Brain and Central Nervous System Tumors Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Head and Neck Cancer Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Kidney and Bladder Cancer Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Skin Cancer and Melanoma Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Other Cancer Applications Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 38: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Comprehensive and Academic Cancer Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Radiation Oncology Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Ambulatory Surgery Centers and Outpatient Cancer Facilities Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Diagnostic Imaging and Screening Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Pathology and Diagnostic Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Specialty Oncology Clinics and Physician Practices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Home Healthcare and Remote Oncology Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 48: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Radiation-Based Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Imaging-Guided Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Robotic and Navigation-Assisted Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Energy-Based Tumor Treatment Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Software-Enabled and AI-Assisted Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Implantable, Wearable, and Disposable Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 56: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Direct Hospital and Cancer Center Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Integrated Delivery Network Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Distributor and Specialty Supplier Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Ambulatory and Physician-Practice Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Leasing, Managed Service, and Equipment-as-a-Service Models Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 64: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: West Region U.S. Oncology Devices Market Share and Leading Players, 2025
FIGURE 66: West Region Market Share Analysis by State, 2025
FIGURE 67: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: California Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Washington Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Arizona Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Colorado Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Oregon Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Utah Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Nevada Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: New Mexico Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Idaho Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Montana Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Wyoming Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Alaska Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Hawaii Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Northeast Region U.S. Oncology Devices Market Share and Leading Players, 2025
FIGURE 82: Northeast Region Market Share Analysis by State, 2025
FIGURE 83: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: New York Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Massachusetts Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: New Jersey Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Pennsylvania Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Connecticut Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Maine Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Vermont Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: New Hampshire Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Rhode Island Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Delaware Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: South Region U.S. Oncology Devices Market Share and Leading Players, 2025
FIGURE 95: South Region Market Share Analysis by State, 2025
FIGURE 96: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Texas Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Florida Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Georgia Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: North Carolina Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Tennessee Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: South Carolina Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Alabama Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Mississippi Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Louisiana Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Arkansas Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Kentucky Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Oklahoma Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Virginia Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Maryland Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: West Virginia Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Midwest Region U.S. Oncology Devices Market Share and Leading Players, 2025
FIGURE 113: Midwest Region Market Share Analysis by State, 2025
FIGURE 114: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Illinois Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Ohio Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Michigan Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: Minnesota Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: Indiana Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: Wisconsin Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 121: Missouri Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 122: Iowa Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 123: Kansas Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 124: Nebraska Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 125: North Dakota Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 126: South Dakota Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 127: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 128: Company Positioning Matrix
FIGURE 129: Key Player Product Portfolio Benchmarking
FIGURE 130: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 131: Oncology Device Innovation Roadmap
FIGURE 132: Adaptive Radiation Therapy Adoption Roadmap
FIGURE 133: AI-Assisted Oncology Workflow Opportunity Map
FIGURE 134: Robotic and Minimally Invasive Oncology Growth Roadmap
FIGURE 135: Interventional Oncology Technology Opportunity Map
FIGURE 136: Tumor Treating Fields Adoption Roadmap
FIGURE 137: Future Market Scenario Analysis, 2026–2035
FIGURE 138: Disruptive Technologies Impact Matrix
FIGURE 139: Emerging Business Trends Matrix
FIGURE 140: Investment Prioritization Matrix
FIGURE 141: Market Entry Timing Framework
FIGURE 142: Technology Adoption Forecast Framework
FIGURE 143: Capital Replacement Cycle Outlook
FIGURE 144: Strategic Growth Roadmap for U.S. Oncology Device Companies
FIGURE 145: Go-to-Market Strategy Framework
FIGURE 146: Product Positioning and Portfolio Expansion Framework
FIGURE 147: Pricing and Contracting Strategy Framework
FIGURE 148: Mergers, Acquisitions, and Partnership Opportunity Map
FIGURE 149: Report Scope and Disclaimer Framework